CRISPR Diagnostics Patents

CRISPR diagnostics patents cover collateral-cleavage-detection innovations; Cas-enzyme/guide innovations; point-of-care/amplification-free innovations; and multiplexing, readout, and §101-eligibility innovations — with IP held by CRISPR-diagnostics companies and the foundational CRISPR labs (in a field using CRISPR enzymes to DETECT, not edit, genetic sequences). WHY CRISPR DIAGNOSTICS: CRISPR is famous for gene EDITING, but the same target-recognition machinery can be repurposed to DETECT specific DNA/RNA sequences with high SPECIFICITY — when a CRISPR enzyme (Cas13 or Cas12) finds its target via its guide RNA, it triggers 'COLLATERAL' cleavage of nearby reporter molecules, producing an amplified, detectable SIGNAL; this enables fast, cheap, highly specific, often POINT-OF-CARE molecular tests for pathogens (e.g., COVID, where SHERLOCK/DETECTR got emergency authorization), cancer mutations, and genetic markers — a powerful new molecular-diagnostics modality. MAJOR HOLDERS: MAMMOTH BIOSCIENCES (DETECTR — from Jennifer Doudna's work), SHERLOCK BIOSCIENCES (SHERLOCK — from Feng Zhang/Broad), CASPR, plus academic IP (Doudna/Zhang foundational). Collateral-cleavage detection, Cas enzymes/guides, point-of-care/amplification-free, multiplexing, and readout/§101 are the core CRISPR-diagnostics patent domains — and collateral cleavage, Cas/guide, point-of-care, and multiplexing are the open whitespace.

Collateral-cleavage-detection innovations; Cas-enzyme/guide innovations; sensitivity/specificity innovations; and reporter/readout innovations represent core CRISPR-diagnostics patent domains — and the collateral-cleavage detection mechanism and the Cas enzyme/guide that drive it are the foundational, high-value capabilities. COLLATERAL-CLEAVAGE-DETECTION PATENTS: the core invention — certain Cas enzymes (Cas13, Cas12), once ACTIVATED by recognizing their target sequence, indiscriminately ('collaterally') CLEAVE nearby REPORTER probes, converting a single target-recognition event into many cleavage events that produce a detectable, amplified signal (SHERLOCK uses Cas13/RNA, DETECTR uses Cas12/DNA); collateral-cleavage detection methods/assays are core, high-value IP (this mechanism is THE basis of CRISPR diagnostics — and foundational Doudna/Zhang IP). CAS-ENZYME / GUIDE PATENTS: the specific Cas ENZYMES (Cas13a/b, Cas12a, Cas14, and novel variants) and GUIDE-RNA design optimized for sensitive, SPECIFIC target detection (including single-base discrimination for mutations); Cas-enzyme and guide methods are core IP (the enzyme and guide determine sensitivity/specificity). SENSITIVITY / SPECIFICITY PATENTS: achieving the SENSITIVITY (detecting few target molecules) and SPECIFICITY (distinguishing closely-related sequences/single mutations) needed for clinical use — and reducing false results; sensitivity/specificity methods are high-value IP (clinical-grade performance is essential). REPORTER / READOUT PATENTS: the REPORTER probes (cleavage substrates) and how cleavage is read out (fluorescence, lateral-flow strip color change, electronic); reporter/readout methods are valuable. Collateral cleavage, Cas/guide, sensitivity/specificity, and reporter/readout are the highest-value core IP because the detection mechanism and the enzyme/guide that power it are exactly what define a CRISPR diagnostic.

Point-of-care/amplification-free innovations; multiplexing innovations; §101-eligibility-navigating innovations; and integration/workflow innovations represent additional CRISPR-diagnostics patent domains — and making the test simple and field-deployable, detecting many targets, and drafting eligible claims are where practical value and IP defensibility concentrate. POINT-OF-CARE / AMPLIFICATION-FREE PATENTS: making the test SIMPLE, RAPID, and INSTRUMENT-free for use at the point of care (clinic/home/field) — and a key goal, REDUCING or ELIMINATING the separate nucleic-acid AMPLIFICATION step (most molecular tests need PCR/isothermal amplification first, which adds complexity; AMPLIFICATION-FREE CRISPR detection, or integrated one-pot amplification+detection, is a major simplicity advance); point-of-care/amplification-free methods are high-value, distinctive IP (simplicity/speed is what makes CRISPR diagnostics deployable outside labs). MULTIPLEXING PATENTS: detecting MANY targets simultaneously in one test (different Cas enzymes/orthogonal cleavage for multiple pathogens/mutations); multiplexing methods are high-value IP (multi-target panels add clinical value). §101-ELIGIBILITY-NAVIGATING PATENTS: CRISPR-diagnostic claims face Alice/MAYO natural-phenomenon scrutiny — DETECTING a naturally-occurring sequence (and correlating it with disease) risks being deemed an ineligible natural correlation; eligibility-robust claiming focuses on the ENGINEERED, concrete technical METHOD (the specific collateral-cleavage assay, engineered Cas/guide, reporter chemistry, device) rather than the natural correlation; §101-aware claiming is critical, strategic IP (it determines whether you have enforceable claims). INTEGRATION / WORKFLOW PATENTS: integrating sample prep + (amplification) + CRISPR detection + readout into a cartridge/device, and the test workflow; integration/workflow methods are valuable. Point-of-care/amplification-free, multiplexing, §101-robust claiming, and integration are the highest-value application IP because simple, multiplexed, field-deployable tests with enforceable claims are exactly what make CRISPR diagnostics commercially real.

CRISPR diagnostics startup IP strategy must navigate the FOUNDATIONAL CRISPR-detection IP (Doudna/Mammoth's DETECTR and Zhang-Broad/Sherlock's SHERLOCK hold the core collateral-cleavage patents — FTO is central, and the Broad/UC CRISPR dispute touches this space), the CRISPR-tool IP layer (Cas enzymes), the §101 natural-phenomenon problem (detecting natural sequences risks ineligibility — claiming the engineered method is essential), the diagnostics-market reality (CRISPR diagnostics must beat established PCR/molecular tests on speed/cost/simplicity — and PCR is cheap and entrenched, so the value is point-of-care/simplicity), the amplification-free goal (a key differentiator and IP area), the FDA/clinical/CLIA path (regulated diagnostics), the point-of-care opportunity, and a landscape where collateral cleavage, Cas/guide, point-of-care/amplification-free, multiplexing, and §101-robust claims are the durable assets; understand that the core mechanism is foundationally patented, so the durable IP for newcomers is in improved Cas/guides, amplification-free/point-of-care methods, multiplexing, integration/readout, and §101-robust claiming — with point-of-care simplicity and FTO/licensing often the real determinants, and that speed/cost/simplicity, sensitivity/specificity, §101-robust claims, and FTO matter as much as patents; identify whitespace in amplification-free, point-of-care, and multiplexing. CRISPR-DIAGNOSTICS STARTUP IP STRATEGY: IMPROVED CAS/GUIDES, AMPLIFICATION-FREE/POINT-OF-CARE METHODS, MULTIPLEXING, INTEGRATION/READOUT, AND §101-ROBUST CLAIMING ARE THE IP: patent improved Cas enzymes/guides, amplification-free/point-of-care methods, multiplexing, integration/readout, and engineered-method claims; FTO/LICENSING OF FOUNDATIONAL DETECTION IP IS CENTRAL: Mammoth/Doudna (DETECTR) and Sherlock/Zhang-Broad (SHERLOCK) hold core collateral-cleavage IP (and the Broad/UC CRISPR dispute touches this) — analyze FTO and license/design around; §101 IS A MAJOR RISK — CLAIM THE ENGINEERED METHOD, NOT THE NATURAL CORRELATION: detecting a natural sequence risks Mayo/Alice ineligibility — claim the specific engineered collateral-cleavage assay/Cas/guide/reporter/device (concrete technical method), not 'detect sequence X = disease Y'; AMPLIFICATION-FREE/POINT-OF-CARE IS THE KEY DIFFERENTIATOR AND WHITESPACE: eliminating the separate amplification step and making tests simple/instrument-free for the field/home is what makes CRISPR diagnostics worth it over entrenched PCR — high-value, distinctive IP; MUST BEAT PCR ON SPEED/COST/SIMPLICITY: PCR is cheap, accurate, and entrenched — CRISPR diagnostics win on point-of-care speed/simplicity/portability, not lab accuracy; position accordingly; MULTIPLEXING ADDS CLINICAL VALUE: multi-target panels (many pathogens/mutations in one test) are valuable IP; CAS/GUIDE IMPROVEMENTS DRIVE PERFORMANCE: better/novel Cas enzymes and guide design (sensitivity/specificity/single-base discrimination) are core IP; INTEGRATION (CARTRIDGE/DEVICE) ENABLES POINT-OF-CARE: integrating sample-prep + detection + readout into a simple device is valuable; FDA/CLIA GATES DIAGNOSTICS: regulated test clearance and clinical validation essential; SPEED/COST/SIMPLICITY/§101/FTO MATTER AS MUCH AS PATENTS: point-of-care simplicity, performance, enforceable claims, and freedom-to-operate drive value; WHEN TO PATENT: NOVEL CAS/AMPLIFICATION-FREE/MULTIPLEX/INTEGRATION WITH MEASURED PERFORMANCE + ENGINEERED CLAIMS: file once a method shows measured results (sensitivity/limit-of-detection + specificity + time-to-result + amplification-free/point-of-care simplicity + multiplexing) AND can be claimed §101-robustly (engineered method) — measured sensitivity/specificity, point-of-care speed/simplicity, and §101-robust claims are the critical CRISPR-diagnostics IP metrics; KEY FTO CHECKLIST: Mammoth/Doudna (DETECTR/Cas12); Sherlock Biosciences/Zhang-Broad (SHERLOCK/Cas13); Broad/UC CRISPR dispute; CRISPR-tool/Cas IP; collateral-cleavage detection (Cas13/Cas12, reporter cleavage); Cas enzyme/guide (Cas13a/Cas12a/Cas14/novel, single-base discrimination); sensitivity/specificity/false-result reduction; point-of-care/amplification-free/one-pot; multiplexing (orthogonal/multi-target); reporter/readout (fluorescence/lateral-flow/electronic); §101 (engineered method vs natural correlation, Mayo/Alice); sample-prep/cartridge/device integration; FDA/CLIA/clinical.